Intra-Cellular Therapies (NASDAQ: ITCI): Reiterating Buy rating with revised price target=$38

ITCI

Like Seroquel (quetipaine), one of the most widely used drugs for schizophrenia and bipolar depression, Intra-cellular Therapies' ITI-007 also acts as antagonist on 5HT2A receptors (providing antipsychotic and antidepressant action, improving sleep quality, reducing anxiety and agitation). Howeve...

Like Seroquel (quetipaine), one of the most widely used drugs for schizophrenia and bipolar depression, Intra-cellular Therapies' ITI-007 also acts as antagonist on 5HT2A receptors (providing antipsychotic and antidepressant action, improving sleep quality, reducing anxiety and agitation). Howeve...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics